系统性硬化症患者血清可溶性CD40水平升高。
Increased serum soluble CD40 levels in patients with systemic sclerosis.
作者信息
Komura Kazuhiro, Fujimoto Manabu, Matsushita Takashi, Yanaba Koichi, Kodera Masanari, Kawasuji Ayako, Hasegawa Minoru, Takehara Kazuhiko, Sato Shinichi
机构信息
Department of Dermatology, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan.
出版信息
J Rheumatol. 2007 Feb;34(2):353-8. Epub 2007 Jan 15.
OBJECTIVE
To determine serum levels of soluble CD40 (sCD40) and clinical association in patients with systemic sclerosis (SSc).
METHODS
Serum sCD40 levels were examined by ELISA in 49 patients with SSc, 15 patients with systemic lupus erythematosus, and 26 healthy individuals. sCD40 levels in plasma samples, which were obtained at the same time, were also determined. SSc patients were grouped into 22 patients with limited cutaneous SSc (lcSSc) and 27 patients with diffuse cutaneous SSc (dcSSc).
RESULTS
There was no significant difference between sCD40 levels of sera and those of plasma. Serum sCD40 levels were significantly elevated in patients with SSc compared to patients with systemic lupus erythematosus and controls (p < 0.001). Serum sCD40 levels were higher in patients with lcSSc than in those with dcSSc (p <0.001). There was no correlation between sCD40 and sCD40 ligand levels in patients with SSc.
CONCLUSION
Elevated serum sCD40 levels were associated with lcSSc. These results suggest that the blockade of CD40/CD40 ligand interaction could be a potential therapeutic strategy in SSc.
目的
测定系统性硬化症（SSc）患者血清可溶性CD40（sCD40）水平及其临床相关性。
方法
采用酶联免疫吸附测定法（ELISA）检测49例SSc患者、15例系统性红斑狼疮患者及26名健康个体的血清sCD40水平。同时测定所采集血浆样本中的sCD40水平。将SSc患者分为22例局限性皮肤型SSc（lcSSc）患者和27例弥漫性皮肤型SSc（dcSSc）患者。
结果
血清与血浆中的sCD40水平无显著差异。与系统性红斑狼疮患者及健康对照相比，SSc患者的血清sCD40水平显著升高（p < 0.001）。lcSSc患者的血清sCD40水平高于dcSSc患者（p < 0.001）。SSc患者的sCD40与sCD40配体水平之间无相关性。
结论
血清sCD40水平升高与lcSSc相关。这些结果表明，阻断CD40/CD40配体相互作用可能是SSc的一种潜在治疗策略。
Zotero 插件